ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 336

The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab

DL Kendler1, A Chines2, ML Brandi3, S Papapoulos4, EM Lewiecki5, J-Y Reginster6, C Roux7, M Munoz Torres8, A Wang2 and HG Bone9, 1University of British Columbia, Vancouver, BC, Canada, 2Amgen Inc., Thousand Oaks, CA, 3University of Florence, Florence, Italy, 4Leiden University Medical Center, Leiden, Netherlands, 5New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 6University of Liège, Liège, Belgium, 7Paris Descartes University, Paris, France, 8Hospital Universitario San Cecilio, Granada, Spain, 9Michigan Bone and Mineral Clinic, Detroit, MI

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: denosumab, fractures, osteoporosis and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Session Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Osteoporosis is a common, progressive condition leading to increased bone fragility and susceptibility to fracture.  Although osteoporosis therapy decreases fracture risk, fractures while on any current treatment can occur and do not necessarily represent treatment failure.  It is therefore of interest to assess whether patients who fracture on denosumab (FREEDOM and FREEDOM Extension) experience a lower risk of subsequent fracture continuing on therapy than those on placebo who have fractured.

Methods:  During FREEDOM, postmenopausal women with osteoporosis were randomized to placebo or denosumab for 3 years.  During the 7-year Extension, all participants were allocated to receive denosumab.  In this analysis, we report subsequent osteoporotic fractures (new vertebral or nonvertebral) in subjects who received ≥2 doses of denosumab during FREEDOM or the Extension, had an osteoporotic fracture while on treatment, and continued treatment post-fracture, compared with subsequent fractures in FREEDOM placebo subjects.  These subsequent fractures were analyzed as recurrent events using the stratified Cox model with the robust variance estimation adjusting for prior fracture.  

Results:  During FREEDOM, 438 placebo and 272 denosumab subjects had an osteoporotic fracture (mean age at first on-study fracture: 74.1 and 74.5 years, respectively).  Of these, there were 54 (12.3%) and 24 (8.8%) subjects who had ≥1 subsequent fractures in the placebo and denosumab groups, respectively.  Adjusted subject incidence per 100 patient-years was lower for denosumab (6.7) vs placebo (10.1).  Combining all subjects on denosumab from FREEDOM and the Extension for up to 10 years, 794 (13.7%) subjects had an osteoporotic fracture while on denosumab (mean age at first on-study fracture: 76.5 years).  Of these, one or more subsequent fractures occurred in 144 (18.1%) subjects, with an adjusted subject incidence of 5.8 per 100 patient-years, similar to FREEDOM denosumab (6.7 per 100 patient-years).  Among subjects with ≥1 subsequent fracture, 90% had only 1, and spine fracture was most frequent.  The risk of having subsequent on-study osteoporotic fractures was lower in all denosumab subjects compared with placebo subjects (HR 0.60 [95% CI: 0.43–0.81]; p=0.0012; Figure).

Conclusion:  The risk of a second fracture with continued denosumab treatment remains lower than placebo, thus suggesting that a fracture sustained while on denosumab is not necessarily indicative of a treatment failure, and continuation of treatment should be considered.

 


Disclosure: D. Kendler, Amgen, Astalis, Astra Zeneca, Eli Lilly, 2,Amgen, Eli Lilly, Merck, 5,Board representative to Doctors of BC, 6,Amgen, Eli Lilly, Merck, 8; A. Chines, Amgen, 1,Amgen, 3; M. Brandi, Amgen, Spa, Bruno Farmaceutics, Abiogen, Eli Lilly, Shire, Alexion, 2,Shire, 8; S. Papapoulos, Amgen, Axsome, Merck, Mereo Biopharma, UCB, 5; E. Lewiecki, Amgen, Merck, Lilly, 2,Amgen, Merck, Lilly, Shire, Alexion, 5,Shire, 8; J. Y. Reginster, Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed-Takeda, NPS, IBSA-Genevrier, Theramex, UCB, Asahi Kasei, Endocyte, Radius Health, 5,Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Merckle, Teijin, Teva, Analis, Theramex, Nycomed, NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Amgen, 9,Bristol Myers Squibb, Merck Sharp and Dohme, Rottapharm, Teva, Roche, Amgen, Lilly, Novartis, GlaxoSmithKline, Servier, Pfizer, Theramex, Danone, Organon, Therabel, Boehringer, Chiltern, Galapagos, 2; C. Roux, MSD, Ultragenyx, 2,Amgen, MSD, UCB, Alexion, 5; M. Munoz Torres, Lilly, Amgen, Alexion, MSD, 8; A. Wang, Amgen Inc., 1,Amgen Inc., 3; H. Bone, Amgen, Merck, Shire, 2,Amgen, Merck, Shire, 5,Amgen, 8.

To cite this abstract in AMA style:

Kendler D, Chines A, Brandi M, Papapoulos S, Lewiecki E, Reginster JY, Roux C, Munoz Torres M, Wang A, Bone H. The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-risk-of-subsequent-osteoporotic-fractures-is-decreased-in-patients-experiencing-fracture-while-on-denosumab/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risk-of-subsequent-osteoporotic-fractures-is-decreased-in-patients-experiencing-fracture-while-on-denosumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences